Get the content you want anytime you want.
The Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019)

Select coverage from The Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019) is included below:

Advancements in HIV Treatment and Prevention
Brian Woodfall, MD, shares his opinion on some of the biggest advancements in HIV treatment and prevention.
Paul Sax, MD, Reacts to Results of ATLAS & FLAIR Studies
Paul Sax, MD, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.
What Should Clinicians Know About Long-Acting Injectables?
Susan Swindells, MBBS, provides an overview of long-acting injectable cabotegravir + rilpivirine for clinicians.
Why Is the Opioid Overdose Death Rate Higher in People With HIV?
Karin Bosh, PhD, explains why the opioid overdose death rate was higher in 2015 than in 2011 among people with HIV.
Are There Risks Associated With Non-Prescription PrEP Use?
PrEP isn’t covered by health insurance in Germany, and non-prescription use of the HIV preventive is common. But is it safe?
Novel PrEP Formulations Could Increase Uptake, Survey Finds
A survey of MSM and transgender women found that diverse formulations and regimens for PrEP, such as long-acting injectables and “on-demand” PrEP, could increase uptake and persistence.
Implementing a PrEP Prediction Model
Julia Marcus, PhD, MPH, provides advice for health care systems looking to implement a model to identify potential PrEP candidates.  
Botswana Beat Cohort Study and the Safety of Dolutegravir in Pregnancy
Ava Avalos, MD, details the effects of a dolutegravir-based regimen on pregnancy.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?